Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals Inc (NQ: ANEB )

3.280 -0.190 (-5.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,749
Open 3.280
Bid (Size) 1.310 (2)
Ask (Size) 3.550 (4)
Prev. Close 3.470
Today's Range 3.250 - 3.300
52wk Range 1.770 - 4.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
H.C. 
Via Benzinga

Performance

YTD
+44.49%
+44.49%
1 Month
+16.73%
+16.73%
3 Month
+50.44%
+50.44%
6 Month
+20.15%
+20.15%
1 Year
+15.09%
+15.09%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
Anebulo Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication
Via Benzinga
Latest Executive Changes In Marijuana Industry, New Appointments & Resignations
Via Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Acute Cannabinoid Intoxication: This Pharma Company's Clinical Trials To Reduce And Treat Symptoms
Via Benzinga
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Crown Holdings Shares Are Trading Lower By Around 22%? Here Are 46 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.